Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. / Boye, Theresa Louise; Steenholdt, Casper; Jensen, Kim Bak; Nielsen, Ole Haagen.

In: Stem Cells, Vol. 40, No. 5, 2022, p. 447-457.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Boye, TL, Steenholdt, C, Jensen, KB & Nielsen, OH 2022, 'Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease', Stem Cells, vol. 40, no. 5, pp. 447-457. https://doi.org/10.1093/stmcls/sxac014

APA

Boye, T. L., Steenholdt, C., Jensen, K. B., & Nielsen, O. H. (2022). Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. Stem Cells, 40(5), 447-457. https://doi.org/10.1093/stmcls/sxac014

Vancouver

Boye TL, Steenholdt C, Jensen KB, Nielsen OH. Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. Stem Cells. 2022;40(5):447-457. https://doi.org/10.1093/stmcls/sxac014

Author

Boye, Theresa Louise ; Steenholdt, Casper ; Jensen, Kim Bak ; Nielsen, Ole Haagen. / Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. In: Stem Cells. 2022 ; Vol. 40, No. 5. pp. 447-457.

Bibtex

@article{3c3192ac495d4a49935f028fa9f388fe,
title = "Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease",
abstract = "The pathogenesis of inflammatory bowel diseases (IBD) involves genetic predisposition, environmental factors, and a broadly dysregulated intestinal immune response to the commensal intestinal microflora. The interface between genetic predisposition and environmental factors is reflected in the epigenetic regulation at the transcriptional level. Treatment targets now involve mucosal and histological healing, but the future might additionally include normalization of intestinal cellular functions also at the molecular level, for example comprising complete restoration of phenotypic, genotypic, and epigenetic states. Recent developments in patient-derived epithelial intestinal stem cell (ISC) organoid technologies have opened exciting new therapeutic opportunities to potentially attain molecular healing by combining stem cell therapy with molecular manipulations using (epi)drugs and/or CRISPR/Cas9 genome editing. Here, we are the first to discuss the possibility for phenotypic, genotypic, and epigenetic restoration via molecular manipulations and stem cell therapy in IBD from a clinical perspective.",
author = "Boye, {Theresa Louise} and Casper Steenholdt and Jensen, {Kim Bak} and Nielsen, {Ole Haagen}",
note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2022",
doi = "10.1093/stmcls/sxac014",
language = "English",
volume = "40",
pages = "447--457",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press, Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease

AU - Boye, Theresa Louise

AU - Steenholdt, Casper

AU - Jensen, Kim Bak

AU - Nielsen, Ole Haagen

N1 - © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2022

Y1 - 2022

N2 - The pathogenesis of inflammatory bowel diseases (IBD) involves genetic predisposition, environmental factors, and a broadly dysregulated intestinal immune response to the commensal intestinal microflora. The interface between genetic predisposition and environmental factors is reflected in the epigenetic regulation at the transcriptional level. Treatment targets now involve mucosal and histological healing, but the future might additionally include normalization of intestinal cellular functions also at the molecular level, for example comprising complete restoration of phenotypic, genotypic, and epigenetic states. Recent developments in patient-derived epithelial intestinal stem cell (ISC) organoid technologies have opened exciting new therapeutic opportunities to potentially attain molecular healing by combining stem cell therapy with molecular manipulations using (epi)drugs and/or CRISPR/Cas9 genome editing. Here, we are the first to discuss the possibility for phenotypic, genotypic, and epigenetic restoration via molecular manipulations and stem cell therapy in IBD from a clinical perspective.

AB - The pathogenesis of inflammatory bowel diseases (IBD) involves genetic predisposition, environmental factors, and a broadly dysregulated intestinal immune response to the commensal intestinal microflora. The interface between genetic predisposition and environmental factors is reflected in the epigenetic regulation at the transcriptional level. Treatment targets now involve mucosal and histological healing, but the future might additionally include normalization of intestinal cellular functions also at the molecular level, for example comprising complete restoration of phenotypic, genotypic, and epigenetic states. Recent developments in patient-derived epithelial intestinal stem cell (ISC) organoid technologies have opened exciting new therapeutic opportunities to potentially attain molecular healing by combining stem cell therapy with molecular manipulations using (epi)drugs and/or CRISPR/Cas9 genome editing. Here, we are the first to discuss the possibility for phenotypic, genotypic, and epigenetic restoration via molecular manipulations and stem cell therapy in IBD from a clinical perspective.

U2 - 10.1093/stmcls/sxac014

DO - 10.1093/stmcls/sxac014

M3 - Journal article

C2 - 35365825

VL - 40

SP - 447

EP - 457

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -

ID: 302045202